Advertisement

Treatment and Prevention of Migraine

  • Paolo Martelletti
  • Ivano Farinelli
Reference work entry

Abstract

Migraine exerts a significant impact on quality of life. Several drugs are available for acute therapy of migraine attacks, namely, specific such as triptans or generic such as analgesics/anti-inflammatory. In some cases, prophylaxis therapy is taken into account according to both attack frequency and severity. In the past, the most common criterion applied for prophylaxis therapy was represented by the number of attacks per month. Considering such a pattern essential, the suggested number of attacks per month was of five or more episodes. At a later date, demand for prophylaxis also considered consumption of symptomatic drugs as well as increase of migraine frequency in a short period of time. Today, prophylaxis therapy is evaluated according to its impact on patients. Therefore, a general evaluation of the patient in terms of functional disability and quality of life is required to assess the appropriateness of prophylaxis therapy, as well as evaluating the risk of medication overuse or the presence of concomitant pathologies (e.g., hypertension, depression, epilepsy). Furthermore, in cases where the condition reaches a level of chronicity (chronic migraine), new options are available today in prophylaxis therapy.

Keywords

Migraine Attack Chronic Migraine Naproxen Sodium Preventive Therapy Sodium Valproate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ashcroft DM, Millson D (2004) Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 13:73–82PubMedCrossRefGoogle Scholar
  2. Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT I trial. Cephalalgia 30:793–803. doi:10.1177/0333102410364676PubMedCrossRefGoogle Scholar
  3. Balbisi EA (2004) Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract 58:695–705PubMedCrossRefGoogle Scholar
  4. Brandes JL, Saper JR, Diamond M et al (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965–973PubMedCrossRefGoogle Scholar
  5. Brandes JL, Kudrow D, Stark SR et al (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297:1443–1454PubMedCrossRefGoogle Scholar
  6. Chen LC, Ashcroft DM (2008) Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 48:236–247PubMedCrossRefGoogle Scholar
  7. Codispoti JR, Prior MJ, Fu M et al (2001) Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 41:665–679PubMedCrossRefGoogle Scholar
  8. Couch JR, Hassanein RS (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36:695–699PubMedGoogle Scholar
  9. Dahlöf CG, Pascual J, Dodick DW et al (2006) Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 26:400–408PubMedCrossRefGoogle Scholar
  10. Dib M, Massiou H, Weber M et al (2002) Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 58:1660–1665PubMedGoogle Scholar
  11. Diener HC, Matias-Guiu J, Hartung E et al (2002) Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 22:209–221PubMedCrossRefGoogle Scholar
  12. Diener HC, Tfelt-Hansen P, Dahlöf C et al (2004) Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 25:943–950Google Scholar
  13. Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814PubMedCrossRefGoogle Scholar
  14. Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936. doi:10.1111/j.1526-4610.2010.01678.xPubMedCrossRefGoogle Scholar
  15. Farinelli I, De Filippis S, Coloprisco G et al (2009) Future drugs for migraine. Intern Emerg Med 4:367–373PubMedCrossRefGoogle Scholar
  16. Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675PubMedCrossRefGoogle Scholar
  17. Goadsby PJ, Ferrari MD, Olesen J et al (2000) Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 54:156–163PubMedGoogle Scholar
  18. Goadsby PJ, Ferrari MD, Csanyi A et al (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29:742–750PubMedCrossRefGoogle Scholar
  19. Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81–84PubMedCrossRefGoogle Scholar
  20. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70(16):1304–1312PubMedCrossRefGoogle Scholar
  21. Kangasniemi P, Hedman C (1984) Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 4:91–96PubMedCrossRefGoogle Scholar
  22. Lampl C, Huber G, Adl J et al (2009) Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol 16:943–948PubMedCrossRefGoogle Scholar
  23. Lassen LH, Ashina M, Christiansen I et al (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401–402PubMedCrossRefGoogle Scholar
  24. Leone M, Grazzi L, La Mantia L et al (1991) Flunarizine in migraine: a minireview. Headache 31:388–391PubMedCrossRefGoogle Scholar
  25. Linde E, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:D003225Google Scholar
  26. Martelletti P, Farinelli I, Steiner TJ (2008) Acute migraine in the emergency department: extending European principles of management. Intern Emerg Med 3:S17–S24PubMedCrossRefGoogle Scholar
  27. Mathew NT, Kailasam J, Meadors L (2004) Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 44:669–673PubMedCrossRefGoogle Scholar
  28. Pfaffenrath V, Cunin G, Sjonell G et al (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38:184–190PubMedCrossRefGoogle Scholar
  29. Prior MJ, Codispoti JR, Fu M (2010) A randomized, placebo-controlled trial of acetaminophen for treatment of migraine Headache. Headache 50(5):819–933. doi:10.1111/j.1526-4610.2010.01638.xPubMedCrossRefGoogle Scholar
  30. Sandrini G, Cerbo R, Del Bene E et al (2007) Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract 61:1256–1269PubMedCrossRefGoogle Scholar
  31. Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43(2):144–166PubMedCrossRefGoogle Scholar
  32. Silberstein SD, Wilmore LJ (1996) Divalproex sodium: migraine treatment and monitoring. Headache 36:239–242PubMedCrossRefGoogle Scholar
  33. Steiner TJ, Paemeleire K, Jensen R (2007) European principles of management of common headache disorders in primary care. J Headache Pain 8:S1–S47Google Scholar
  34. Stovner LJ, Tronvik E, Hagen K (2009) New drugs for migraine. J Headache Pain 10:395–406PubMedCrossRefGoogle Scholar
  35. Suthisisang CC, Poolsup N, Suksomboon N et al (2010) Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 50:808–818PubMedCrossRefGoogle Scholar
  36. Taylor FR (2010) Acute treatment of migraine headaches. Semin Neurol 30(2):145–153PubMedCrossRefGoogle Scholar
  37. The Diclofenac-K/Sumatriptan Migraine Study Group, Bussone G, Grazzi L, D'Amico D (1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 19:232–240CrossRefGoogle Scholar
  38. Tronvik E, Stovner LJ, Helde G et al (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69PubMedCrossRefGoogle Scholar
  39. Weiss B, Alt A, Ogden AM, Gates M et al (2006) Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 318:772–781PubMedCrossRefGoogle Scholar

Copyright information

© Lifting The Burden 2011

Authors and Affiliations

  1. 1.Department of Medical and Molecular SciencesSchool of Health Sciences, Sapienza University of RomeRomeItaly

Personalised recommendations